Company profile: MabVax Therapeutics
1.1 - Company Overview
Company description
- Provider of proprietary anti-cancer immunotherapies as a biopharmaceutical company focused on their commercialization.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MabVax Therapeutics
Stemline
HQ: United States
Website
- Description: Provider of targeted oncology therapies and investigational medicines, including ELZONRIS (tagraxofusp), a CD123-directed therapy approved for BPDCN and being evaluated in AML, CMML, and myelofibrosis, and ORSERDU (elacestrant), an oral SERD approved for ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Pipeline includes SL-801 (XPO1 inhibitor), SL-701 (glioblastoma immunotherapy), and Expanded Access Programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Stemline company profile →
Tusk Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapies, discovering and developing unique therapeutic antibodies that harness the immune system to treat cancer, with a growing, diversified pipeline targeting both novel and validated targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tusk Therapeutics company profile →
Medigene
HQ: Germany
Website
- Description: Provider of biotechnology solutions for cancer treatment, offering an end-to-end platform for developing TCR-guided therapies—including TCR-T, TCR-T cell engagers, and TCR-natural killer cell therapies—focused on specificity, sensitivity, and safety. Pipeline includes MDG1015 (NY-ESO-1/LAGE-1a, PD1-41BB) and MDG2011 (KRAS G12V, PD1-41BB) for solid tumors, plus 3S TCR technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medigene company profile →
TORL Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TORL Biotherapeutics company profile →
Coordination Pharma
HQ: United States
Website
- Description: Provider of nanoparticle-based anticancer therapies, including CPI-100, which delivers immunostimulatory chemotherapeutic combinations directly to tumors. Offers the NCP platform using nanoscale coordination polymers to develop products targeting solid tumors, and seeks partnership opportunities to enhance current cancer immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coordination Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MabVax Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MabVax Therapeutics
2.2 - Growth funds investing in similar companies to MabVax Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MabVax Therapeutics
4.2 - Public trading comparable groups for MabVax Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →